Clinical trials: TACE, completed
Hepatocellular Carcinoma (HCC)
A Pilot Study of Trans Arterial Chemoembolization (TACE), Followed by Stereotactic Radiation Therapy (SBRT) for Patients With Hepatocellular Carcinoma
This investigational study will evaluate if using a combination of TACE along with high dose SBRT would show improvement in local control in patients with Hepatocellular Carcinoma.
- Trial name
- RAD 0902 (NCT01247298)
- Testing
- Stereotactic Body Radiation Therapy (SBRT)
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- University of Alabama at Birmingham
Carcinoma, Hepatocellular
Phase III Study of BAY43-9006 in Patients With Advanced Hepatocellular Carcinoma (HCC) Treated After Transcatheter Arterial Chemoembolization (TACE)
Clinical trial of BAY43-9006 in patients with hepatocellular carcinoma.
- Trial name
- NCT00494299
- Testing
- Sorafenib (Nexavar, BAY43-9006)
- Where
- 75 sites in Japan, South Korea
- Volunteers
- 458 people
- Sponsor
- Bayer
HCC
Sequential TACE and SBRT Followed by ImmunoTherapy for Downstaging HCC for Hepatectomy
This study is a prospective phase II, single arm clinical study conducted in Queen Mary Hospital (Hong Kong) assessing the efficacy and safety of the sequential administration of trans-arterial chemo-embolization (TACE) and…
- Trial name
- START-FIT (NCT03817736)
- Testing
- TACE, SBRT, Immune Checkpoint Inhibitor
- Where
- Hong Kong
- Volunteers
- 33 people
- Sponsor
- The University of Hong Kong
Liver Cancer
Chemoembolization of the Liver With or Without Sunitinib Malate in Treating Patients With Liver Cancer
RATIONALE: Chemoembolization kills tumor cells by blocking the blood flow to the tumor and keeping anticancer drugs near the tumor.
- Trial name
- SATURNE (NCT01164202)
- Testing
- sunitinib malate, transarterial chemoembolization
- Where
- 31 sites in France
- Volunteers
- 78 people
- Sponsor
- Federation Francophone de Cancerologie Digestive
Hepatocellular Carcinoma
Hepatocellular Carcinoma (HCC) Transarterial Chemoembolisation (TACE) +Axitinib
The survival of subjects with unresectable hepatocellular carcinoma (HCC) receiving transarterial chemoembolization is improved with addition of axitinib.
- Trial name
- NCT01352728
- Testing
- Axitinib
- Where
- Hong Kong
- Volunteers
- 50 people
- Sponsor
- Chinese University of Hong Kong
HepatoCellular Carcinoma
HAIC Versus TACE for Large Hepatocellular Carcinoma Staged BCLC A/B.
The purpose of this study is to evaluate the efficacy and safety of hepatic arterial infusion chemotherapy (HAIC) compared with transarterial chemoembolization (TACE) in patients with large hepatocellular carcinoma staged BCLC…
- Trial name
- NCT02973685
- Testing
- Hepatic arterial infusion chemotherapy, Transarterial chemoembolization, Folfox Protocol
- Where
- 3 sites in China
- Volunteers
- 315 people
- Sponsor
- Sun Yat-sen University
Primary Liver Cancer
Prospective Randomised Study of Doxorubicin in the Treatment of Hepatocellular Carcinoma by Drug-Eluting Bead Embolisation
The objective of this study is to assess the safety and efficacy of DC Bead™ delivered by intra-arterial embolisation for the treatment of Hepatocellular Carcinoma
- Trial name
- PRECISIONV (NCT00261378)
- Testing
- Transarterialchemoembolisation (TACE), DC Bead with Doxorubicin
- Where
- 17 sites in Austria, France and 2 more
- Volunteers
- 212 people
- Sponsor
- Boston Scientific Corporation
Hepatocellular Carcinoma (HCC)
Immune Checkpoint Inhibitors and Anti-vascular Endothelial Growth Factor Antibody/Tyrosine Kinase Inhibitors With or Without TACE for Advanced HCC With Vascular Invasions
Immune checkpoint inhibitors and anti-vascular endothelial growth factor antibody/tyrosine kinase inhibitors with or without transarterial chemoembolization as first-line treatment for advanced hepatocellular carcinoma with…
- Trial name
- NCT06881446
- Where
- China
- Volunteers
- 2,651 people
- Sponsor
- Zhongda Hospital
Hepatocellular Carcinoma
Combined Therapy for Hepatocellular Carcinoma >3-<5 cm
The purpose of this study is to compare the safety and efficacy of combined therapy with conventional transarterial chemoembolization (cTACE) + microwave ablation (MWA) versus only TACE or MWA for treatment of hepatocellular…
- Trial name
- NCT04721470
- Testing
- Combined therapy, Microwave ablation, Transarterial chemoembolization
- Volunteers
- 278 people
- Sponsor
- Zagazig University
Carcinoma, Hepatocellular
CT Imaging for Guiding PA-TACE for HCC
Postoperative adjuvant transarterial chemoembolization (PA-TACE) may improve survival outcomes in a subset of patients with resected hepatocellular carcinoma (HCC), reliable biomarkers for the criterion for the selection of…
- Trial name
- NCT06156748
- Testing
- postoperative adjuvant transarterial chemoembolization
- Where
- China
- Volunteers
- 1,770 people
- Sponsor
- Zhujiang Hospital
Hepatocellular Carcinoma
Transarterial Chemoembolization (TACE) Therapy of Hepatocellular Carcinoma (HCC) With Blocking Tumor Blood Temporarily and Enhancing Perfusion
According to radiology imaging, the patients of HCC are divided into two groups(hypovascular tumor group and moderately vascular tumor group).
- Trial name
- NCT00826384
- Testing
- balloon catheter
- Where
- China
- Volunteers
- 352 people
- Sponsor
- Eastern Hepatobiliary Surgery Hospital
Colon Cancer With Metastases to the Liver
Drug-Eluting Bead, Irinotecan (DEBIRI) Therapy of Liver Metastasis From Colon Cancer With Systemic Fluorouracil, Oxaliplatin, Leucovorin and Bevacizumab
This is a multicentre, open labeled, controlled phase study designed to assess effectiveness of chemoembolization with LC Beads, both with and without systemic chemotherapy, in the treatment of unresectable liver metastases in…
- Trial name
- DEBIRI (NCT00932438)
- Testing
- LC beads loaded with Irinotecan, Oxaliplatin, Leucovorin
- Where
- 10 sites in United States, Argentina
- Volunteers
- 70 people
- Sponsor
- University of Louisville
Hepatocellular Carcinoma
Hepatocellular Carcinoma Registry for Turkey (3K Trial)
This registry study is national, multi-center, prospective study without any interventions to the treatment strategies and/or decisions of the investigators.
- Trial name
- NCT01473121
- Testing
- No Intervention
- Where
- Turkey (Türkiye)
- Volunteers
- 600 people
- Sponsor
- Bayer
Hepatocellular Carcinoma, Unresectable Hepatocellular Carcinoma
Chemoembolization With or Without Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery
This randomized phase III trial studies chemoembolization and sorafenib tosylate to see how well they work compared with chemoembolization alone in treating patients with liver cancer that cannot be removed by surgery.
- Trial name
- NCT01004978
- Testing
- Cisplatin, Computed Tomography, Doxorubicin Hydrochloride
- Where
- 281 sites in United States
- Volunteers
- 235 people
- Sponsor
- National Cancer Institute (NCI)
Hepatocellular Carcinoma
A Simple Prognostic Scoring System for Patients Receiving Transarterial Chemoembolization for Hepatocellular Carcinoma
Hepatocellular carcinoma (HCC) is the 6th most common cancer worldwide and the third most frequent cause of death of cancer.Although with the development of medical science, more and more patients diagnose HCC at early stage, a…
- Trial name
- NCT02061956
- Where
- China
- Volunteers
- 647 people
- Sponsor
- Sun Yat-sen University
Hepatocellular Carcinoma Non-resectable
Lenvatinib Plus DEB-TACE With/Without FOLFOX-HAIC for Large HCC With PVTT
This multicenter retrospective study evaluated consecutive patients with large HCC and PVTT who received lenvatinib plus DEB-TACE with/without FOLFOX-HAIC between July 2019 and June 2021.
- Trial name
- NCT06265883
- Testing
- Len+DEB-TACE+HAIC, Len+DEB-TACE
- Where
- China
- Volunteers
- 205 people
- Sponsor
- Second Affiliated Hospital of Guangzhou Medical University
Hepatocellular Carcinoma
TACE in Combination With PD-1/PD-L1 Inhibitors and Molecular Target Therapies for Advanced HCC
The purpose of this study is to evaluate the safety and efficacy of transarterial chemoembolization (TACE) in combination with immune checkpoint inhibitors (ICIs) and molecular target therapies in patients with advanced-stage…
- Trial name
- CHANCE2201 (NCT05332821)
- Testing
- PD-1/PD-L1 inhibitors+VEGF-TKI/bevacizumab, TACE
- Where
- 2 sites in China
- Volunteers
- 1,244 people
- Sponsor
- Zhongda Hospital
Non-metastatic Hepatocellular Carcinoma
Transarterial Chemoembolization Plus Hypofractionnated Radiotherapy vs. Surgery in Locally Advanced Hepatocellular Carcinoma: an IPTW Comparison
Patients with non-metastatic unresectable hepatocellular carcinoma
- Trial name
- TACE-hypoRT (NCT04823715)
- Testing
- TACE + hypofractionated EBRT, Surgical resection
- Where
- France
- Volunteers
- 163 people
- Sponsor
- Hospices Civils de Lyon
Hepatocellular Carcinoma (HCC)
AI Multitask Model for HCC Treatment
We will integrate multi-modal cardiac data via an AI multitask framework to develop and validate concurrent models for liver function, treatment prognosis, and microvascular invasion (MVI) prediction in hepatocellular carcinoma.
- Trial name
- NCT07157085
- Testing
- Comprehensive treatment
- Where
- China
- Volunteers
- 7,000 people
- Sponsor
- Sun Yat-sen University
Uveal Melanoma
Transarterial Radioembolisation in Comparison to Transarterial Chemoembolisation in Uveal Melanoma Liver Metastasis
Characterisation of effect of SIRT and DSM-TACE as local treatment options for liver metastases in patients with advanced uveal melanoma with respect to progression-free survival and exploratory comparison of secondary endpoints…
- Trial name
- SirTac (NCT02936388)
- Testing
- SIRT, DSM-TACE
- Where
- Germany
- Volunteers
- 108 people
- Sponsor
- Charite University, Berlin, Germany